chromosome 20 open reading frame 202Genealiases: []
Q-omics provides the consensus-scored C20orf202 profile across patient tissues and cancer cell-line models. C20orf202 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, C20orf202 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, C20orf202 RNA expression shows 17,402 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KIRC, and UVM as cancer lineages where C20orf202 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C20orf202 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C20orf202 survival associations across molecular data types. C20orf202 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C20orf202 RNA expression–survival associations across cancer types. High C20orf202 expression shows unfavorable associations in MESO, ACC and LUSC, but favorable associations in HNSC, READ and BLCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for C20orf202 RNA expression.
This table summarizes C20orf202 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for C20orf202. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C20orf202 shows lower tumor expression in LUAD and LUSC and higher tumor expression in KIRC, LIHC, STAD and CHOL. The KIRC box plot shows higher C20orf202 RNA expression in tumor versus normal tissue (log2 FC = +0.788, t-test p < 0.001).
This table shows molecular features associated with C20orf202 in patient tissues and cancer cell lines. In patient samples, C20orf202 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, C20orf202 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Lymphoma.
